BioSpace News Archive

McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2022 financial results after market close on Wednesday, February 2, 2022.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company.

Aditxt, Inc. today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore™ and securing worldwide exclusivity in all fields of use of the licensed technology (the “Technology”).

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board (“IRB”) approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.

Gardiner Healthcare Acquisitions Corp. (NASDAQ: GDNRU, the “Company”) announced today that an additional 1,125,000 units were issued pursuant to the underwriters’ exercise in full of its over-allotment option in connection with the Company’s initial public offering.

Tevogen Bio, today announced that the U.S. Patent and Trademark Office (USPTO) has granted patent of the pharmaceutical compositions of its investigational SARS-CoV-2 Specific Allogeneic T cell therapy for treatment of COVID-19 (US 11,207,401).

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference.

BiondVax Pharmaceuticals Ltd. announced the closing of an underwritten public offering of 4,144,068 American Depositary Shares at a public offering price of $2.36 per ADS for gross proceeds to the Company of approximately $9.8 million in the aggregate, inclusive of the successful execution of the full over-allotment, before deducting underwriting discounts and other offering expenses.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.